Result for
Topic: Vaccines and Immunity
October 15, 2020
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
In a randomized placebo-controlled phase 1/2 trial of a SARS-CoV-2 vaccine candidate, BBIBP-CorV, 192 healthy adults were randomized to receive vaccine (2, 4, or 8 μg) or placebo in a 3:1 ratio, stratified by age (18-59 and ≥60) in phase 1. Adverse reactions within the first 7 days of inoculation were reported by 42 (29%)…
Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection
Geometric mean SARS-CoV-2 neutralizing antibody titers of 18 SARS-CoV-2 positive patients in South Korea decreased from 219.4 at 2 months to 143.7 at 5 months (p=0.03) after infection, indicating a waning antibody response. The decline was significantly associated with antibody levels at 2 months and happened more frequently in symptomatic patients who developed pneumonia (n=11),…
October 9, 2020
Antibody Responses after COVID-19 Infection in Patients Who Are Mildly Symptomatic or Asymptomatic in Bangladesh
A study of antibody responses after COVID-19 infection in patients in Bangladesh indicated that while people who had mild symptoms generated an immune response, those who had no symptoms had lower antibody levels or did not generate any detectable immune response. IgM and IgA responses developed by day 14 after confirmation of infection in 72%…
Persistence of Serum and Saliva Antibody Responses to SARS-CoV-2 Spike Antigens in COVID-19 Patients
Profiling of IgG, IgA, and IgM antibody response to the SARS-CoV-2 spike protein and its receptor-binding domain (RBD) indicated that anti-SARS-CoV-2 antibody responses were readily detected in serum and saliva from patients with COVID-19, with peak IgG levels occurring 16 to 30 days after symptom onset. IgA and IgM antibodies rapidly decayed over time, although…
October 7, 2020
Antibody Reactivity to SARS-CoV-2 in Adults from the Vancouver Metropolitan Area Canada
[Pre-print, not peer-reviewed] A substantial proportion of individuals who lacked serological evidence of SARS-CoV-2 exposure showed antibody reactivity against SARS-CoV-2 antigens, possibly due to cross-reactivity of antibodies against other coronaviruses. Among 276 adults tested for SARS-CoV-2 antibodies during the second wave of the COVID-19 pandemic in Vancouver, Canada (May 17-June 19, 2020), 3 participants tested…
An In-Depth Investigation of the Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine
[Pre-print, not peer-reviewed] Administration of two inoculations of an inactivated SARS-CoV-2 vaccine was evaluated as safe and immunogenic in a phase I study in China. A double-blinded trial randomly assigned 192 healthy adults to receive one of the three doses of the vaccine or the placebo at an interval of 14 days or 28 days….
October 2, 2020
Waning of SARS-CoV-2 RBD Antibodies in Longitudinal Convalescent Plasma Samples within Four Months after Symptom Onset
A decrease in anti-RBD antibodies was observed over time in a study of individuals who had recovered from SARS-CoV-2 and who gave repeated blood donations. The study determined that the decline was not due to repeated donations, but rather that the anti-RBD response wanes over time of convalescence. The response was found to be relatively…
Intention to Participate in a COVID-19 Vaccine Clinical Trial and to Get Vaccinated against COVID-19 in France during the Pandemic
Nearly 75% of respondents in an online survey in France said they were likely to get a COVID-19 vaccine, and almost half indicated they might agree to participate in a clinical trial for the vaccine. The anonymous online survey indicated that healthcare workers were more likely to report that they would get vaccinated or participate…
October 1, 2020
Expert Forecasts of COVID-19 Vaccine Development Timelines
Among 28 vaccine experts (20 Canada, 6 US) with 25 median years of experience working with vaccines (range 8–42), 53% said the pace of COVID-19 research is increasing the potential for errors. The median probability forecast that a vaccine would receive a black box warning label for a widely deployed vaccine was 30% and that…
September 29, 2020
Safety and Immunogenicity of SARS-CoV-2 MRNA-1273 Vaccine in Older Adults
A phase 1, dose escalation trial of a messenger RNA vaccine against SARS-CoV-2 conducted among adults ages 56-70 (n=20) and ages 71 or older (n=20) reported generating antibody response with mild to moderate adverse events. Serum neutralizing activity was detected in all participants and was similar in magnitude to responses previously reported among participants between…
Previous page Next page